C
Cornelis J.A. Haasbeek
Researcher at VU University Amsterdam
Publications - 80
Citations - 7423
Cornelis J.A. Haasbeek is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: SABR volatility model & Lung cancer. The author has an hindex of 33, co-authored 72 publications receiving 5689 citations. Previous affiliations of Cornelis J.A. Haasbeek include VU University Medical Center.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +21 more
TL;DR: SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death.
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer
TL;DR: SRT is well tolerated in patients with extensive comorbidity with high local control rates and minimal toxicity, and such risk-adapted SRT schedules should be considered treatment of choice in patients presenting with medically inoperable Stage I NSCLC.
Journal ArticleDOI
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis
TL;DR: Late recurrences after SABR are infrequent and two distinct patterns account for most cases; the predominant pattern is out-of-field, isolated distant recurrence presenting early, despite initial PET staging.